TIMP1 and breast carcinoma: This finding is consistent with studies in colorectal cancer, where TIMP1 knockdown sensitized cells to sorafenib-induced ferroptosis (25, 26, 29), and breast cancer, where TIMP1 expression correlated with chemoresistance (42, 43).